The Urinary Tract Infections drugs in development market research report provides comprehensive information on the therapeutics under development for Urinary Tract Infections, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Urinary Tract Infections. Buy the report here.
Smarter leaders trust GlobalData
The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Urinary Tract Infections and features dormant and discontinued products.
GlobalData tracks 112 drugs in development for Urinary Tract Infections by 89 companies/universities/institutes. The top development phase for Urinary Tract Infections is preclinical with 33 drugs in that stage. The Urinary Tract Infections pipeline has 109 drugs in development by companies and three by universities/ institutes. Some of the companies in the Urinary Tract Infections pipeline products market are: Helperby Therapeutics Group, GSK and Entasis Therapeutics.
The key targets in the Urinary Tract Infections pipeline products market include Beta Lactamase (EC 3.5.2.6), Penicillin Binding Protein (PBP), and Penicillin Binding Protein 2 (PBP2).
The key mechanisms of action in the Urinary Tract Infections pipeline product include Beta Lactamase (EC 3.5.2.6) Inhibitor with 17 drugs in Pre-Registration. The Urinary Tract Infections pipeline products include 12 routes of administration with the top ROA being Intravenous and 12 key molecule types in the Urinary Tract Infections pipeline products market including Small Molecule, and Biologic.
Urinary Tract Infections overview
A urinary tract infection (UTI) is a bacterial infection that can occur in any part of the urinary system, including the kidneys, bladder, ureters, and urethra. Common symptoms include pain or burning during urination, frequent urination, urgency, lower abdominal discomfort, and cloudy or foul-smelling urine. UTIs are more common in women, and risk factors include factors such as sexual activity, urinary tract abnormalities, and weakened immune systems. Diagnosis is typically based on symptoms and a urine sample analysis. Treatment involves antibiotics, and preventive measures include staying hydrated, practicing good hygiene, and urinating before and after sexual activity. Prompt medical attention is important to prevent complications, such as kidney infections.
For a complete picture of Urinary Tract Infections’s pipeline drug market, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.
